Global Thrombectomy Device Market to Reach USD 2.3 Billion by 2032, Driven by Rising Stroke Cases and Breakthrough Device Innovations
The global Thrombectomy Device Market is set for robust expansion, USD 1.2 billion in 2024, growing at a CAGR of 8 %. The growth is fueled by a surge in ischemic stroke incidence, technological innovation in device design, and increasing adoption of mechanical thrombectomy as the standard of care worldwide.
Thrombectomy devices used to remove blood clots from vessels in acute ischemic stroke, pulmonary embolism, and peripheral arterial occlusions are gaining clinical and commercial momentum. Hospitals and specialized stroke centers are rapidly upgrading interventional capabilities, driven by the urgent global push for faster revascularization and improved patient outcomes.
Rising Stroke Burden and Expanding Indications
Globally, stroke continues to be a leading cause of death and disability, accounting for over 12 million new cases annually. The growing elderly population and prevalence of hypertension, diabetes, and atrial fibrillation are significantly increasing the number of patients eligible for endovascular thrombectomy.
In recent years, evidence-based clinical trials have shown that timely mechanical thrombectomy significantly improves recovery rates and reduces long-term disability compared to traditional thrombolysis. As a result, thrombectomy is now recommended by most major stroke treatment guidelines across North America, Europe, and Asia-Pacific.
Market Insights and Segment Highlights
Stent retrievers dominate the thrombectomy device market with an estimated 45% share, followed by aspiration catheters 35%, both expected to maintain steady growth through 2032. Acute ischemic stroke remains the leading application segment, representing nearly 60% of the market, while pulmonary embolism interventions are emerging as the fastest-growing category, expanding at a rate of 10% annually.
Hospitals and stroke centers account for the majority of procedures, supported by an expanding network of neurointerventional units and government-funded stroke programs. The Asia-Pacific region is expected to post the highest growth at 10.2% CAGR, driven by increasing healthcare investments, growing awareness, and rapid urbanization in China and India.
Recent Industry Developments
In April 2025, Surmodics announced that its Pounce XL Thrombectomy System received U.S. FDA 510(k) clearance for treatment of thrombi in peripheral arteries 5.5–10 mm in diameter, broadening the company’s platform for large-vessel mechanical thrombectomy beyond the previous 2–6 mm vessels.
In October 2024, Penumbra announced the completion of enrollment for its THUNDER IDE trial, which is evaluating its next-generation computer assisted vacuum thrombectomy (CAVT) technology for acute ischemic stroke patients using the Penumbra System with Thunderbolt aspiration tubing.
In July 2025, Inari Medical now a Stryker company announced the commercial launch of the second-generation InThrill Thrombectomy System, the first device purpose-built for arteriovenous access and small-vessel clot removal, signaling a move into previously challenging vascular territories.
Technological Evolution and Future Outlook
Emerging technologies are redefining the thrombectomy landscape. Manufacturers are focusing on miniaturized, flexible catheters, AI-guided imaging systems, and hybrid aspiration-stent retriever solutions for enhanced clot removal precision.
Innovations targeting medium and distal vessel occlusions are set to open new treatment frontiers, while the development of thrombectomy platforms for pulmonary embolism and deep venous thrombosis (DVT) will further diversify market opportunities.
Additionally, the growing integration of tele-stroke systems and AI-assisted diagnostics is reducing treatment delays, improving patient selection, and expanding the eligible patient base for thrombectomy procedures especially in developing regions.
Competitive Landscape
The global thrombectomy device industry is led by key players including Medtronic, Stryker, Penumbra, Inc., Boston Scientific, and Terumo Corporation, collectively accounting for nearly 48% of the total market share. These companies continue to focus on device optimization, bundled service models, and physician training programs to strengthen clinical adoption.
Strategic collaborations with imaging solution providers and hospitals are further driving integrated stroke management ecosystems. Value-based procurement models and managed device programs are gaining attention among healthcare providers seeking cost-effective, outcome-oriented solutions.
Market Outlook
As hospitals and governments prioritize reducing stroke-related mortality and long-term disability, thrombectomy devices are positioned as essential tools for modern neurovascular care. Ongoing innovations, clinical research, and favorable reimbursement frameworks are expected to sustain long-term growth through 2032 and beyond.
About Author:
HTF Market Intelligence Consulting is uniquely positioned to empower and inspire with research and consulting services to empower businesses with growth strategies, by offering services with extraordinary depth and breadth of thought leadership, research, tools, events, and experience that assist in decision-making.